8635 W. 3rd St. Suite #485-W
Los Angeles, CA 90048
(310) 652-9162

Evonne Daza

Education

2008

Associates Degree in Science

1999

Licensed Emergency Medical Technician

1992

Diploma in X-ray

1992

Medical Assistant


Experience

1999-present

Clinical Research Coordinator
Tower Nephrology, Los Angeles, CA

Responsibilities include: Obtain informed consent, complete and maintain case report forms, maintain regulatory file, perform computerized assessments (Medidata, Fisheract), Interactive voice response system, Notify IRB of all serious adverse events, develop and negotiate study budgets and contracts.

1994-1999

X-ray Technician / Medical Assistant

Tower Nephrology, Los Angeles
Performed X-rays, EKG.S, Phlebotomy, injections, and IV therapy


Research Study Locations

  • Tower Nephrology
  • Da Vita Beverly Hills Dialysis Center
  • Da Vita Crescent Heights Dialysis Center

Clinical Studies

2013 Dangerous Good Certification (Certificate)
2013 ICH Good Clinical Practice for Clinical Trial Sites
2010 GCP Certified by the National Cancer Institute
2010 Dangerous Goods Certification

2014 Ferumoxytol for Anemia of CDK Trial (FACT): A Phase IV, Open-Label, Multicenter Trial, with MRI Substudy, of Repeated Doses of Ferumoxytol Compared with Iron Sucrose for the Treatment of Iron Definiency Anemia (IDA) in Chronic Kidney Disease
(CDK) Patients on Hemodialysis
2014 A Multicenter Single-arm Extention Study to Describe the Long-term Efficacy and
Safety of AMG 416 in the Treatment of Secondary Hyperparathroidism in Subjects With Chronic Kidney Disease on Hemodialysis
2013 A randomized, Double-blind, Placebo-controlled, Phase 3 Study to assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathroidism in Subjects With
Chronic Kidney Disease on Hemodialysis
2013 ICH Good Clinical Practice for Clinical Trial Sites
2013 ZS-003: “A Phase III multicenter, Two-phase, Multi-dose, Prospective, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of ZS (Microporous, Fractionated, Protonated Zirconium Silicate), an Oral Sorbent, in Subjects with Mild to Moderate Hyperkalemia.
2013 Randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of HX575 epoetin alfa vs. US licensed epoetin alfa (Epogen /Procrit) in the treatment of anemia associated with chronic kidney disease.
2013 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily Administration of a Chemokine CCR2/5 Receptor Antagonist (PF-04634817) in Adults With Type 2 Diabetes and Overt Nephropathy Study #B1261007-1137
2012 A phase 2b, Prospective, Double- Blind, Placebo- Controlled, Multicenter to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedence, in Type Diabetic Subjects with Nephropathy
2011 A Three-Period, 58-Week Safety and Effiancy Trial of KRX-0502 (ferric citrate) in Patients with End-Stage Renal Disease (ESRD) on Dialysis
2011 Bardoxolone Methyl Evaluation in patients with chronic kidney disease and type 2 diabetes: The occurrence of renal events (Beacon)
2011 A Randomized, Placebo-Controlled, Phase III Study of Dialysate Containing Soluble Ferric Pyrophosphate (SFP) in Chronic Kidney Disease Patients Receiving Hemodialysis: The Continuous Replacement Using Iron Soluble Equivalents (CRUISE 2) Study
2010

A 30-Week, multicenter, randomized, double-blind, parallel-group study of the combination of ABT-335 and Rosuvastatin compared to Rosuvastatin Monotherapy in Dyslipidemic subjects with Stage 3 Chronic Kidney Disease.

2010

Study to evaluate the improved management of iPTH with paracalcitol- centered therapy vs. cinacalcet therapy with low-dose vitamin d in hemodialysis patients with secondary hyperparathyroidism.

2009

A Phase 2a, prospective, randomized, double-blind, placebo-controlled multicenter study to evaluate the safety and efficacy of Atrasentan on reducing albuminuria in type 2 diabetic nephropathy subjects who are currently being treated with an renin-angiotensin system inhibitor.

2008

Phase 2, randomized, double-blind, placebo-controlle, parallel group, fixed dose study of AMG 223 in subjects with chronic kidney disease on hemodialysis with hyperphosphatemia.

2007

A Phase III, Randomized, active-controlled, open-label, multi-center study of the safety and efficacy of AF37702 injection for the maintenance treatment of anemia in hemodialysis patients previously treated with epoetin

2007

Outcome trial evaluating the efficacy and safety of Norditropin® on adult patients on chronic haemodialysis

2007

A Phase IV, Long-term, Observational Safety Study in End Stage Renal Disease Subjects treated with lanthanum Carbonate (Fosrenol ®)

2007

A Two-Arm, Randomized, Open-Label, Multicenter Study of Safety and Efficacy of Monthly Injections of RO0503821 versus Epoetin Alfa in Peritoneal Dialysis patients who self inject or receive in-center Injections.

2007

Prospective, Open Label, Randomized multicenter study to demonstrate the efficacy and safety of intravenous (IV) RO0503821 for hemoglobin control in patients transitioning from chronic kidney disease. Stage 4 through dialysis.

2007

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic kidney Disease Progression in Patients with Moderate to Severe Chronic Kidney Disease.

2007

A Randomized, Open-Label, multicenter study Epoetin Alfa comparing two extended-dosing regimens, Once-every-Two-Weeks, and Once- Every-Four-Weeks, with the Once-Weekly dosing regimen for maintenance treatment in anemic subjects with chronic kidney disease

2007

An Open Label Randomized, Paralled-Group, Clinical Endpoint Bioequivalence Study of Generic Iron Sucrose Injection USP Versus Venofer® Iron Sucrose Injection USP in Hemodialysis Patients with Iron Deficiency

2006

A randomized, double blind, placebo controlled, parallel group study to assess the effect of the endothelin receptor antagonist avosentan on time to doubling of serum creatinine, end stage renal disease or death in patients with type 2diabetes mellitus and diabetic nephropathy.

2006

Evaluation Of Cinacalcet HCI Therapy to Lower cardio Vascular Events.

2006

A Phase III Study if the Safety and Efficacy of Ferumoxytol (compared with oral iron) as an Iron Replacement Therapy in Chronic Kidney Disease Patients not on Dialysis.

2005

An Open-Label, Single-Arm Study to Assess the Safety of Darbepoetin Alfa Manufactured by a Serum Free Bioreactor Technology in Subjects with Chronic Kidney Disease.

2004

Phase IIIb, Multi-Center, Two-Cohort, Randomized Study, with an Open-Label Run-In and a Long-Term Extension Phase, Assessing an Extended Dose Range of Lanthanum Carbonate in End Stage Renal Disease Subjects Receiving Hemodialysis.

2004

Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Efficacy of Staph VAX, a Bivalent Staphylococcus aureus Glycoconjugate Vaccine in Adults on Hemodialysis.

2003

Phase 3 Cinacalcet open label to reach K/DOQI levels

2003

Phase 3 trial in treatment Strategies to Achieve Recommended K/DOQI Goals in ESRD Patients on Cinacalce.

2003

Phase 4 Prospective, Randomized, double-blind, double-dummy, forced- titration, multicenter, parallel group, one year treatment trial to compare MICARDIS (telmisartan) 80 mg versus COZAAR (losartan) 100mg, in hypertensive type 2 diabetic patients with overt nephropathy (AMADEO Study)

2003

Phase 3 Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of an Oral Calcimimetic Agent When Two Different Vitamin D Regimens are used in Subjects with Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD).

2002

Phase 4 to evaluate subject preference for Aranesp administered administered once monthly, ie every 4 weeks (Q4W) or procrit administered once weekly (QW).

2002

Phase 3 Placebo-controlled, Double-blind, Extension Study to Assess the Long-term Safety of an Oral Calcimimetic Agent in Secondary Hyperparathyroidism of End-Stage Renal Disease.

2002

Phase 4 Disease/Case Management of Patients Receiving ARANESP (darbepoetin alfa) to Treat the Anemia of Chronic Renal Insufficiency (CRI).

2002

Phase 4, Multicenter Trial Using Once Every Other Week Subcutaneous Administration of Aranesp (darbepoetin alfa) and Iron Guided Algorithms to Treat Subjects with Anemia of Chronic Renal Insufficiency (CRI).

2002

Phase 4 Multicenter Study Evaluating Once Every Other Week Subcutaneous Administration of Aranesp (darbepoetin alfa) in subjects with Anemia of Chronic Renal Insufficiency (CRI).

2002

Phase 3 Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent on Secondary Hyperparathyroidism of End Stage Renal Disease Treated with Hemodialysis.

2001

Phase 3 A Multicenter, Open-label Extension Study to Assess the Long- term Safety and Efficacy if an Oral Calcimimetic Agent in Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD).

2001

Phase 2 Randomized, double-blind Study to Assess the Efficacy and safety of an Oral Calcimimetic Agent on secondary Hyperparathyroidism of End Stage Renal Disease treated with Hemodialysis.

2000

Phase 2 Pharmacokinetic (PK) Analysis of Chronic Subcutaneous (SC) Novel Erythropoiesis Stimulating Protein (NESP) Therapy in Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis (HD).

1999

Chronic Renal Insufficiency registry in a prospective, observational study designed to gather data on the use of various interventions delivered to patients with renal insufficiency, pre-ESRD.

1999

Randomized Study Comparing the Efficiency of Once Weekly Versus 3 Times Weekly Administration of Subcutaneous (SC) Novel Erythropoiesis Stimulating Protein (NESP) to Subjects with End-Stage Renal Disease (ESRD) Receiving Hemodialysis.